drugset / Trial / NCT06999031
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Phase 0
Recruiting
12 enrolled
The First Affiliated Hospital of Nanchang University
Cells & Genes Biotech (Shanghai) Co.,Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-105-12 in the participants with BCMA-positive relapsed/refractory multiple myeloma who previously received adequate but uneffective standard treatments.
Timeline
- Start
- 2024-09-05
- Primary completion
- 2026-04-05
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CG-105-12 | Cell therapy | — | — |